메뉴 건너뛰기




Volumn 72, Issue 1, 2008, Pages 116-120

Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease

Author keywords

Argatroban; Endovascular intervention; Heparin induced thrombocytopenia; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN; WARFARIN;

EID: 47549085223     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21595     Document Type: Article
Times cited : (9)

References (31)
  • 1
    • 4043152705 scopus 로고    scopus 로고
    • Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the NHANES 1999-2000
    • Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the NHANES 1999-2000. Circulation 2004;110:738-743.
    • (2004) Circulation , vol.110 , pp. 738-743
    • Selvin, E.1    Erlinger, T.P.2
  • 2
    • 3242719852 scopus 로고    scopus 로고
    • Understanding trends in inpatient surgical volume: Vascular interventions, 1980-2000
    • Anderson PL, Gelijns A, Moskowitz A, et al. Understanding trends in inpatient surgical volume: Vascular interventions, 1980-2000. J Vasc Surg 2004;39:1200-1208.
    • (2004) J Vasc Surg , vol.39 , pp. 1200-1208
    • Anderson, P.L.1    Gelijns, A.2    Moskowitz, A.3
  • 4
    • 0027971564 scopus 로고
    • Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
    • Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JAI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699.
    • (1994) Blood , vol.84 , pp. 3691-3699
    • Warkentin, T.E.1    Hayward, C.P.M.2    Boshkov, L.K.3    Santos, A.V.4    Sheppard, J.A.I.5    Bode, A.P.6    Kelton, J.G.7
  • 5
    • 0027959329 scopus 로고
    • Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and recombinant Hirudin
    • Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and recombinant Hirudin. Thromb Haemost 1994;72:381-386.
    • (1994) Thromb Haemost , vol.72 , pp. 381-386
    • Berry, C.N.1    Girardot, C.2    Lecoffre, C.3    Lunven, C.4
  • 6
    • 0035836541 scopus 로고    scopus 로고
    • Argatroban anticoagulation in patients with heparin-induced thrombocytopenia
    • Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
    • (2001) Circulation , vol.103 , pp. 1838-1843
    • Lewis, B.E.1    Wallis, D.E.2    Leya, F.3
  • 8
    • 0001184962 scopus 로고    scopus 로고
    • Argatroban versus heparin as adjuvant therapy to thrombolysis for actue myocardial infarction: Safety considerations-ARGAMI-2 Study
    • Behar S, Hod H, Kaplinski E. Argatroban versus heparin as adjuvant therapy to thrombolysis for actue myocardial infarction: Safety considerations-ARGAMI-2 Study. Circulation 1998;98 (Suppl 17): 1453-1454.
    • (1998) Circulation , vol.98 , Issue.SUPPL. 17 , pp. 1453-1454
    • Behar, S.1    Hod, H.2    Kaplinski, E.3
  • 9
    • 0031419066 scopus 로고    scopus 로고
    • Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis
    • Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997; 23:531-534.
    • (1997) Semin Thromb Hemost , vol.23 , pp. 531-534
    • Kobayashi, S.1    Tazaki, Y.2
  • 10
    • 0036792725 scopus 로고    scopus 로고
    • Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    • Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-184.
    • (2002) Catheter Cardiovasc Interv , vol.57 , pp. 177-184
    • Lewis, B.E.1    Matthai Jr, W.H.2    Cohen, M.3
  • 11
    • 12444322211 scopus 로고    scopus 로고
    • Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study
    • Jang IK, Lewis BE, Matthai WH Jr., Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004;18:31-37.
    • (2004) J Thromb Thrombolysis , vol.18 , pp. 31-37
    • Jang, I.K.1    Lewis, B.E.2    Matthai Jr., W.H.3    Kleiman, N.S.4
  • 12
    • 47549102419 scopus 로고    scopus 로고
    • Efficacy and sagety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary synfrome
    • Jul 15 [Epub ahead of print
    • Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ, Healy JL, Watanabe H, Osakabe M, Yeh RW, Jang IK. Efficacy and sagety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary synfrome. J Thromb Thrombolysis 2007; Jul 15 [Epub ahead of print].
    • (2007) J Thromb Thrombolysis
    • Cruz-Gonzalez, I.1    Sanchez-Ledesma, M.2    Baron, S.J.3    Healy, J.L.4    Watanabe, H.5    Osakabe, M.6    Yeh, R.W.7    Jang, I.K.8
  • 13
    • 0023258694 scopus 로고
    • Thrombolysis in myocardial infarction (TIMIT) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge
    • Chesebro JH, Knatterud, Roberts R, et al. Thrombolysis in myocardial infarction (TIMIT) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142-154.
    • (1987) Circulation , vol.76 , pp. 142-154
    • Chesebro, J.H.1    Knatterud, R.R.2
  • 14
    • 6344281156 scopus 로고    scopus 로고
    • Heparin induced thrombocytopenia: Myths and misconceptions (that will cause trouble for you and your patient)
    • Rice L. Heparin induced thrombocytopenia: Myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 2004;164:1961-1964.
    • (2004) Arch Intern Med , vol.164 , pp. 1961-1964
    • Rice, L.1
  • 15
    • 0036213008 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia: An overview
    • Kelton JG. Heparin-induced thrombocytopenia: An overview. Blood Rev 2002;16:77-80.
    • (2002) Blood Rev , vol.16 , pp. 77-80
    • Kelton, J.G.1
  • 16
    • 0030934251 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia/thrombosis syndrome (HIT): Diagnosis and treatment
    • Baglin TP. Heparin-induced thrombocytopenia/thrombosis syndrome (HIT): Diagnosis and treatment. Platelets 1997;8:72-82.
    • (1997) Platelets , vol.8 , pp. 72-82
    • Baglin, T.P.1
  • 17
    • 0030281338 scopus 로고    scopus 로고
    • A 14 year study of heparin-induced thrombocytopenia
    • Warkentin TE, Kelton JG. A 14 year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
    • (1996) Am J Med , vol.101 , pp. 502-507
    • Warkentin, T.E.1    Kelton, J.G.2
  • 18
    • 0033029056 scopus 로고    scopus 로고
    • Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
    • Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-635.
    • (1999) Am J Med , vol.106 , pp. 629-635
    • Wallis, D.E.1    Workman, D.L.2    Lewis, B.E.3    Steen, L.4    Pifarre, R.5    Moran, J.F.6
  • 19
    • 0038285887 scopus 로고    scopus 로고
    • Argatroban anticoagulation in patients with heparin-oinduced thrombocytopenia
    • Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-oinduced thrombocytopenia. Arch Intern Med 2003;163:1849-1856.
    • (2003) Arch Intern Med , vol.163 , pp. 1849-1856
    • Lewis, B.E.1    Wallis, D.E.2    Leya, F.3    Hursting, M.J.4    Kelton, J.G.5
  • 20
    • 0030052674 scopus 로고    scopus 로고
    • Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin
    • Lunven C, Gauffeny C, Lecoffre C, et al. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996;75:154-160.
    • (1996) Thromb Haemost , vol.75 , pp. 154-160
    • Lunven, C.1    Gauffeny, C.2    Lecoffre, C.3
  • 21
    • 0026694104 scopus 로고
    • Persistent inhibition of artieral thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor
    • Jang IK, Gold HR, Leinbach RC, et al. Persistent inhibition of artieral thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coron Artery Dis 1992;2: 407-414.
    • (1992) Coron Artery Dis , vol.2 , pp. 407-414
    • Jang, I.K.1    Gold, H.R.2    Leinbach, R.C.3
  • 22
    • 0025648376 scopus 로고
    • In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator
    • Jang IK, Gold HK, Leinbach RC, et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990;67:1552-1561.
    • (1990) Circ Res , vol.67 , pp. 1552-1561
    • Jang, I.K.1    Gold, H.K.2    Leinbach, R.C.3
  • 24
    • 2942665487 scopus 로고    scopus 로고
    • Small-molecule direct antithrombins: Argatroban
    • Fareed J, Jeske WP. Small-molecule direct antithrombins: Argatroban. Best Pract Res Clin Haematol 2004;17:127-138.
    • (2004) Best Pract Res Clin Haematol , vol.17 , pp. 127-138
    • Fareed, J.1    Jeske, W.P.2
  • 25
    • 3042593381 scopus 로고    scopus 로고
    • Argatroban anticoagulation in patients with acute ischemic stroke
    • LaMonte MP, Marshall LN, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke. Stroke 2004;35:1677-1682.
    • (2004) Stroke , vol.35 , pp. 1677-1682
    • LaMonte, M.P.1    Marshall, L.N.2    Wang, D.Z.3
  • 26
    • 19644398319 scopus 로고    scopus 로고
    • When heparins promote thrombosis: Review of heparin-induced thrombocytopenia
    • Jang IK, Hursting MJ. When heparins promote thrombosis: Review of heparin-induced thrombocytopenia. Circulation 2005; 111:2671-2683.
    • (2005) Circulation , vol.111 , pp. 2671-2683
    • Jang, I.K.1    Hursting, M.J.2
  • 27
    • 0030880463 scopus 로고    scopus 로고
    • Long-term mortality and its predictor's in patients with critical leg ischaemia. The I.C.A.I. Group. Eur J Vasc Endocasv Surg 1997;14:91-95.
    • Long-term mortality and its predictor's in patients with critical leg ischaemia. The I.C.A.I. Group. Eur J Vasc Endocasv Surg 1997;14:91-95.
  • 28
    • 33645810153 scopus 로고    scopus 로고
    • Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal mesenteric, and abdominal aortic, A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery. Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease, endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463
    • Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery. Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463.
  • 30
    • 0030979952 scopus 로고    scopus 로고
    • Adjunctive therapy with an antithrommbotic drug can prevent reocclusion and induce residual thrombus reduction after percutaneous transcatheter angioplasty of the thrombotic lesions
    • Kawano H, Tomaru T, Omata M, Okada R, Uchida Y. Adjunctive therapy with an antithrommbotic drug can prevent reocclusion and induce residual thrombus reduction after percutaneous transcatheter angioplasty of the thrombotic lesions. J Thromb Thrombolysis 1997;4:293-300.
    • (1997) J Thromb Thrombolysis , vol.4 , pp. 293-300
    • Kawano, H.1    Tomaru, T.2    Omata, M.3    Okada, R.4    Uchida, Y.5
  • 31
    • 0000270291 scopus 로고
    • Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban
    • Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban. J Thromb Thrombolysis 1995;2:131-136.
    • (1995) J Thromb Thrombolysis , vol.2 , pp. 131-136
    • Matsuo, T.1    Kario, K.2    Matsuda, S.3    Yamaguchi, N.4    Kakishita, E.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.